Literature DB >> 22491086

A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothers.

Paige L Williams1, George R Seage, Russell B Van Dyke, George K Siberry, Raymond Griner, Katherine Tassiopoulos, Cenk Yildirim, Jennifer S Read, Yanling Huo, Rohan Hazra, Denise L Jacobson, Lynne M Mofenson, Kenneth Rich.   

Abstract

The Pediatric HIV/AIDS Cohort Study's Surveillance Monitoring of ART Toxicities Study is a prospective cohort study conducted at 22 US sites between 2007 and 2011 that was designed to evaluate the safety of in utero antiretroviral drug exposure in children not infected with human immunodeficiency virus who were born to mothers who were infected. This ongoing study uses a "trigger-based" design; that is, initial assessments are conducted on all children, and only those meeting certain thresholds or "triggers" undergo more intensive evaluations to determine whether they have had an adverse event (AE). The authors present the estimated rates of AEs for each domain of interest in the Surveillance Monitoring of ART Toxicities Study. They also evaluated the efficiency of this trigger-based design for estimating AE rates and for testing associations between in utero exposures to antiretroviral drugs and AEs. The authors demonstrate that estimated AE rates from the trigger-based design are unbiased after correction for the sensitivity of the trigger for identifying AEs. Even without correcting for bias based on trigger sensitivity, the trigger approach is generally more efficient for estimating AE rates than is evaluating a random sample of the same size. Minor losses in efficiency when comparing AE rates between persons exposed and unexposed in utero to particular antiretroviral drugs or drug classes were observed under most scenarios.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22491086      PMCID: PMC3390009          DOI: 10.1093/aje/kwr401

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  38 in total

Review 1.  Quantitative methods in pharmacovigilance: focus on signal detection.

Authors:  Manfred Hauben; Xiaofeng Zhou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.

Authors:  Susan B Brogly; Mark J Abzug; D Heather Watts; Coleen K Cunningham; Paige L Williams; James Oleske; Daniel Conway; Rhoda S Sperling; Hans Spiegel; Russell B Van Dyke
Journal:  Pediatr Infect Dis J       Date:  2010-08       Impact factor: 2.129

3.  Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study).

Authors:  Steven E Lipshultz; William T Shearer; Bruce Thompson; Kenneth C Rich; Irene Cheng; E John Orav; Sulekha Kumar; Ricardo H Pignatelli; Louis I Bezold; Philip LaRussa; Thomas J Starc; Julie S Glickstein; Sharon O'Brien; Ellen R Cooper; James D Wilkinson; Tracie L Miller; Steven D Colan
Journal:  J Am Coll Cardiol       Date:  2011-01-04       Impact factor: 24.094

4.  Validation of a portable hand-held lactate analyzer for determination of blood lactate in patients on antiretroviral therapy in Uganda.

Authors:  Agnes K Kiragga; Ponsiano Ocama; Steven J Reynolds; Andrew Kambugu; Henry Ojiambo; Barbara Castelnuovo
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-15       Impact factor: 3.731

5.  Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-01-30

6.  Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Authors:  Ellen R Cooper; Manhattan Charurat; Lynne Mofenson; I Celine Hanson; Jane Pitt; Clemente Diaz; Karen Hayani; Edward Handelsman; Vincent Smeriglio; Rodney Hoff; William Blattner
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

Review 7.  Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants.

Authors:  Lynne M Mofenson; Paula Munderi
Journal:  J Acquir Immune Defic Syndr       Date:  2002-06-01       Impact factor: 3.731

8.  Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women.

Authors: 
Journal:  J Acquir Immune Defic Syndr       Date:  2003-04-01       Impact factor: 3.731

9.  Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.

Authors:  Jeffrey Ferranti; Monica M Horvath; Heidi Cozart; Julie Whitehurst; Julie Eckstrand
Journal:  Pediatrics       Date:  2008-05       Impact factor: 7.124

10.  Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006.

Authors:  Claire L Townsend; Mario Cortina-Borja; Catherine S Peckham; Annemiek de Ruiter; Hermione Lyall; Pat A Tookey
Journal:  AIDS       Date:  2008-05-11       Impact factor: 4.177

View more
  29 in total

1.  Antiretroviral Drugs in Meconium: Detection for Different Gestational Periods of Exposure.

Authors:  Sarah K Himes; Katherine Tassiopoulos; Ram Yogev; Marilyn A Huestis
Journal:  J Pediatr       Date:  2015-05-19       Impact factor: 4.406

2.  Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers.

Authors:  Steven E Lipshultz; Paige L Williams; Bret Zeldow; James D Wilkinson; Kenneth C Rich; Russell B van Dyke; George R Seage; Laurie B Dooley; Jonathan R Kaltman; George K Siberry; Lynne M Mofenson; William T Shearer; Steven D Colan
Journal:  AIDS       Date:  2015-01-02       Impact factor: 4.177

3.  Dramatic decline in substance use by HIV-infected pregnant women in the United States from 1990 to 2012.

Authors:  Kathryn Rough; Katherine Tassiopoulos; Deborah Kacanek; Raymond Griner; Ram Yogev; Kenneth C Rich; George R Seage
Journal:  AIDS       Date:  2015-01-02       Impact factor: 4.177

4.  Risk for Speech and Language Impairments in Preschool Age HIV-exposed Uninfected Children With In Utero Combination Antiretroviral Exposure.

Authors:  Mabel L Rice; Jonathan S Russell; Toni Frederick; Murli Purswani; Paige L Williams; George K Siberry; Sean M Redmond; Howard J Hoffman; Tzy-Jyun Yao
Journal:  Pediatr Infect Dis J       Date:  2018-07       Impact factor: 2.129

5.  Growth at 2 Years of Age in HIV-exposed Uninfected Children in the United States by Trimester of Maternal Antiretroviral Initiation.

Authors:  Denise L Jacobson; Kunjal Patel; Paige L Williams; Mitchell E Geffner; George K Siberry; Linda A DiMeglio; Marilyn J Crain; Ayesha Mirza; Janet S Chen; Elizabeth McFarland; Deborah Kacanek; Margarita Silio; Kenneth Rich; William Borkowsky; Russell B Van Dyke; Tracie L Miller
Journal:  Pediatr Infect Dis J       Date:  2017-02       Impact factor: 2.129

6.  Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.

Authors:  Sarah K Himes; Julia W Wu; Denise L Jacobson; Katherine Tassiopoulos; Rohan Hazra; Deborah Kacanek; Russell B Van Dyke; Kenneth C Rich; George K Siberry; Marilyn A Huestis
Journal:  Pediatr Infect Dis J       Date:  2015-08       Impact factor: 2.129

7.  Development and validation of the first liquid chromatography-tandem mass spectrometry assay for simultaneous quantification of multiple antiretrovirals in meconium.

Authors:  Sarah K Himes; Karl B Scheidweiler; Katherine Tassiopoulos; Deborah Kacanek; Rohan Hazra; Kenneth Rich; Marilyn A Huestis
Journal:  Anal Chem       Date:  2013-01-14       Impact factor: 6.986

8.  Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design.

Authors:  Paige L Williams; Rohan Hazra; Russell B Van Dyke; Cenk Yildirim; Marilyn J Crain; George R Seage; Lucy Civitello; Angela Ellis; Laurie Butler; Kenneth Rich
Journal:  AIDS       Date:  2016-01-02       Impact factor: 4.177

9.  Cardiac biomarkers in HIV-exposed uninfected children.

Authors:  James D Wilkinson; Paige L Williams; Erin Leister; Bret Zeldow; William T Shearer; Steven D Colan; George K Siberry; Laurie B Dooley; Gwendolyn B Scott; Kenneth C Rich; Steven E Lipshultz
Journal:  AIDS       Date:  2013-04-24       Impact factor: 4.177

10.  Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.

Authors:  Paige L Williams; Cenk Yildirim; Ellen G Chadwick; Russell B Van Dyke; Renee Smith; Katharine F Correia; Alexandria DiPerna; George R Seage; Rohan Hazra; Claudia S Crowell
Journal:  Lancet HIV       Date:  2019-11-15       Impact factor: 12.767

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.